Department of Anesthesiology, Shenzhen Children's Hospital, Shenzhen, Guangdong, 518038, China.
Everest Medical Care, 2010 West Chester Pike, Havertown, PA, 19083, USA.
Cancer Lett. 2020 Oct 28;491:121-131. doi: 10.1016/j.canlet.2020.07.044. Epub 2020 Aug 12.
Triple-negative breast cancer (TNBC) is the most complex and challenging breast cancer subtype to treat, and chemotherapy remains the standard of care. Clinically, TNBC has a relatively high rate of recurrence and poor prognosis, which leads to a significant effort to discover novel strategies to treat patients with these tumors. Currently, chimeric antigen receptor (CAR) T cell-based immunotherapy redirects the patient's immune system directly to recognize and eradicate tumor-associated antigens (TAAs) expressing tumor cells being explored as a treatment for TNBC. A steadily increasing research in CAR T-cell therapy targeting different TAAs in TNBC has reported. In this review, we introduce the CAR technology and summarize the potential TAAs, available CARs, the antitumor activity, and the related toxicity of CARs currently under investigation for TNBC. We also highlight the potential strategies to prevent/reduce potential "on target, off tumor" toxicity induced by CAR T-cell therapy. This review will help to explore proper targets to expand further the CAR T-cell therapy for TNBCs in the clinic.
三阴性乳腺癌（TNBC）是治疗最复杂和最具挑战性的乳腺癌亚型，化疗仍然是标准的治疗方法。临床上，TNBC的复发率相对较高，预后较差，这导致了人们极大的努力来发现治疗这些肿瘤的新策略。目前，嵌合抗原受体（CAR）T 细胞免疫疗法直接引导患者的免疫系统识别和消除表达肿瘤相关抗原（TAA）的肿瘤细胞，正在探索作为治疗 TNBC 的一种方法。目前，针对 TNBC 中不同 TAA 的 CAR T 细胞治疗的研究不断增加。在这篇综述中，我们介绍了 CAR 技术，并总结了目前正在研究的针对 TNBC 的潜在 TAA、可用的 CAR、抗肿瘤活性以及相关毒性。我们还强调了预防/减少 CAR T 细胞治疗引起的潜在“靶内、脱靶”毒性的潜在策略。这篇综述将有助于探索合适的靶点，进一步扩大 CAR T 细胞疗法在临床上对 TNBC 的应用。
